Akero Therapeutics receives FDA fast track designation for efruxifermin for the treatment of NASH

Akero Therapeutics

19 October 2021 - Akero Therapeutics today announced that the U.S. FDA has granted fast track designation to its lead program investigating efruxifermin for the treatment of non-alcoholic steatohepatitis.

Akero's lead product candidate, efruxifermin is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.

Read Akero Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track